ARTICLE | Company News
Next act for BeiGene’s tislelizumab: a Leap deal for gastric cancer
January 4, 2020 2:15 AM UTC
Updated on Jan 4, 2020 at 6:19 PM UTC
Fresh off the approval of tislelizumab in China, BeiGene has partnered with Leap to pair the PD-1 inhibitor with the latter’s DKK1 inhibitor to create a combination therapy that could help treat cancers that don’t respond to checkpoint inhibitors, such as gastric cancer.
BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) will pay $3 million up front for an exclusive option to DKN-01 in Asia outside of Japan, as well as in Australia and New Zealand. Leap Therapeutics Inc. (NASDAQ:LPTX) is eligible for an undisclosed option fee, which is exercisable after initial proof-of-concept studies; up to $132 million in milestones; and tiered royalties. ...